|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/00 | |
| A61K 9/00 | |||
| A61K 39/395 | |||
| A61P 27/02 | |||
| C07K 16/28 | |||
| C07K 16/22 |
| (11) | Patento numeris | 2575881 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11728594.0 |
| Europos patento paraiškos padavimo data | 2011-05-27 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-04-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-09-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/058777 |
| Data | 2011-05-27 |
| (87) | Numeris | WO 2011/147984 |
| Data | 2011-12-01 |
| (30) | Numeris | Data | Šalis |
| 349271 P | 2010-05-28 | US |
| (72) |
LE BOUTEILLER, Philippe, FR
BENSUSSAN, Armand, FR
|
| (73) |
INSERM - Institut National de la Santé et de la Recherche Médicale,
101, rue de Tolbiac, 75013 Paris,
FR
Elsalys Biotech, 321 avenue Jean Jaures, 69007 Lyon, FR |
| (54) | ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS |
| ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS |